$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

$ptgx Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000162828017008339 Filed on August 08, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$8.781M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.590M	$3.120M	$1.400M
YoY Change	63.92%	122.86%	77.22%
% of Gross Profit
Research & Development	$11.17M	$12.01M	$5.696M
YoY Change	100.83%	110.8%	147.98%
% of Gross Profit
Depreciation & Amortization	$110.0K	$90.00K	$90.00K
YoY Change	37.5%	0.0%	80.0%
% of Gross Profit
Operating Expenses	$13.76M	$15.13M	$7.091M
YoY Change	92.79%	113.38%	130.0%
Operating Profit	-$4.980M	-$15.13M	-$7.091M
YoY Change	-30.23%	113.38%	130.0%
Interest Expense	$160.0K	$150.0K	$30.00K
YoY Change	220.0%	400.0%	-121.43%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$34.00K
YoY Change		-100.0%
Pretax Income	-$4.830M	-$14.98M	-$7.100M
YoY Change	-31.78%	110.99%	120.5%
Income Tax
% Of Pretax Income
Net Earnings	-$4.825M	-$14.98M	-$7.098M
YoY Change	-31.89%	111.03%	120.5%
Net Earnings / Revenue	-54.95%
Basic Earnings Per Share
Diluted Earnings Per Share	-$285.6K	-$887.4K	-$484.3K
COMMON SHARES
Basic Shares Outstanding	16.90M shares	16.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.60M	$64.50M	$20.20M
YoY Change	-4.97%	219.31%
Cash & Equivalents	$50.40M	$10.37M	$13.77M
Short-Term Investments	$43.20M	$54.10M	$6.400M
Other Short-Term Assets	$2.700M	$1.700M	$500.0K
YoY Change	50.0%	240.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$97.70M	$69.13M	$22.42M
YoY Change	-4.44%	208.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$945.0K	$903.0K	$599.0K
YoY Change	67.55%	50.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.30M	$0.00
YoY Change
Other Assets	$0.00	$0.00	$34.00K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$12.71M	$1.353M	$2.099M
YoY Change	2025.59%	-35.54%
TOTAL ASSETS
Total Short-Term Assets	$97.70M	$69.13M	$22.42M
Total Long-Term Assets	$12.71M	$1.353M	$2.099M
Total Assets	$110.4M	$70.48M	$24.52M
YoY Change	7.36%	187.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.267M	$2.639M	$1.441M
YoY Change	-2.91%	83.14%
Accrued Expenses	$8.241M	$6.727M	$2.669M
YoY Change	173.42%	152.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$52.25M	$9.366M	$4.110M
YoY Change	876.76%	127.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$300.0K	$100.0K
YoY Change
Total Long-Term Liabilities	$300.0K	$100.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.25M	$9.366M	$4.110M
Total Long-Term Liabilities	$300.0K	$100.0K	$0.00
Total Liabilities	$52.58M	$9.449M	$4.110M
YoY Change	882.97%	129.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$98.50M	-$93.67M	-$46.26M
YoY Change	84.64%	102.49%
Common Stock	$156.2M	$154.7M	$158.0K
YoY Change	3.56%	97811.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$57.84M	$61.03M	-$46.20M
YoY Change
Total Liabilities & Shareholders Equity	$110.4M	$70.48M	$24.52M
YoY Change	7.36%	187.48%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$4.825M	-$14.98M	-$7.098M
YoY Change	-31.89%	111.03%	120.5%
Depreciation, Depletion And Amortization	$110.0K	$90.00K	$90.00K
YoY Change	37.5%	0.0%	80.0%
Cash From Operating Activities	$40.70M	-$12.32M	-$8.070M
YoY Change	-683.09%	52.66%	133.91%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$370.0K	-$30.00K
YoY Change	280.0%	1133.33%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$580.0K	$13.46M	-$6.010M
YoY Change	-114.76%	-323.96%
Cash From Investing Activities	-$770.0K	$13.09M	-$6.040M
YoY Change	-119.79%	-316.72%	9966.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	90.00K	-750.0K
YoY Change	-99.96%	-112.0%	-1350.0%
NET CHANGE
Cash From Operating Activities	40.70M	-12.32M	-8.070M
Cash From Investing Activities	-770.0K	13.09M	-6.040M
Cash From Financing Activities	30.00K	90.00K	-750.0K
Net Change In Cash	39.96M	860.0K	-14.86M
YoY Change	-51.38%	-105.79%	330.72%
FREE CASH FLOW
Cash From Operating Activities	$40.70M	-$12.32M	-$8.070M
Capital Expenditures	-$190.0K	-$370.0K	-$30.00K
Free Cash Flow	$40.89M	-$11.95M	-$8.040M
YoY Change	-690.04%	48.63%	137.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001377121
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16902761	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PROTAGONIST THERAPEUTICS, INC
	dei	Trading Symbol TradingSymbol	PTGX
	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	265000	USD
	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	0	USD
CY2016Q4	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	3617000	USD
CY2017Q2	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	4299000	USD
CY2016Q4	ptgx	Accrued Milestone Payment AccruedMilestonePayment	0	USD
CY2017Q2	ptgx	Accrued Milestone Payment AccruedMilestonePayment	250000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	85241000	USD
CY2017Q2	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	63438000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	85169000	USD
CY2017Q2	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	63363000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	2000	USD
CY2017Q2	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	0	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	74000	USD
CY2017Q2	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	75000	USD
CY2016Q2	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	4719000	USD
CY2017Q2	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	4194000	USD
	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	0	USD
	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	1030000	USD
	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	479000	USD
	ptgx	Reclassification Of Preferred Stock Warrant Liability To Equity ReclassificationOfPreferredStockWarrantLiabilityToEquity	1005000	USD
	ptgx	Reclassification Of Preferred Stock Warrant Liability To Equity ReclassificationOfPreferredStockWarrantLiabilityToEquity	0	USD
CY2016Q2	ptgx	Remeasured Fair Value Of Warrants RemeasuredFairValueOfWarrants	1000000	USD
CY2016Q4	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	2241000	USD
CY2017Q2	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	2881000	USD
CY2016Q1	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5800000	USD
	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5837000	USD
	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	0	USD
	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	696000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1698000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	152000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	324000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	6435000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	9449000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10269000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18504000	USD
	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1163000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2639000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-72000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-272000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1420000	USD
CY2017Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1338000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5272000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6727000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	115000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	669000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-245000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152393000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	154700000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	162000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1001000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1845000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9887412	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9887412	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2476521	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2476521	shares
CY2016Q4	us-gaap	Assets Assets	93990000	USD
CY2017Q2	us-gaap	Assets Assets	70479000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	83244000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	69126000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	85169000	USD
CY2017Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	63363000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	56515000	USD
CY2017Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	54127000	USD
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	10150000	USD
CY2017Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	42000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13768000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21084000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10365000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4065000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13778000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21094000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10825000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9713000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	181000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-19.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-56.90
CY2017Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	9236000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16722280	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16899261	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16722280	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16899261	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7103000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18843000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14954000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28832000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	83000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	159000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.73
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M16D
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	525000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-34000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	65000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1395000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2810000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3124000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6115000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	85000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1428000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	202000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1517000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1134000	USD
	us-gaap	Operating Expenses OperatingExpenses	29404000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7091000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14131000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93990000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70479000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6435000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9366000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	21881000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	461000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1113000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11843000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13312000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22683000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-7098000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18845000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-14979000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29080000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7323000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19110000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14979000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29080000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	185000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	7091000	USD
	us-gaap	Operating Expenses OperatingExpenses	14131000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	15131000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15131000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29404000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	13389000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2059000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1999000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1941000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1667000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5228000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	495000	USD
CY2016Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	5272000	USD
CY2017Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6727000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	120000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	171000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	11000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	251000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	7788000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	770000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	6396000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8002000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	279000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	420000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3394000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1743000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	22508000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20265000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	143000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	461000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	562000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	903000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5696000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11321000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12007000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23289000	USD
CY2016Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2016Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2017Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2016Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2016Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2017Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	450000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64593000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93700000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93673000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	162000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1845000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	87555000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	61030000	USD
CY2016Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0689655
CY2016Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	225000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	265000	USD
CY2017Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	383910	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	335855	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16875627	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16821225	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.625
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0138
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.26
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and available-for-sale securities. Substantially all of the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and to meet liquidity requirements. The Company’s cash equivalents and available-for-sale securities are managed by external managers within the guidelines of the Company’s investment policy. The Company’s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and available-for-sale securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds. The Company has not experienced any material credit losses on its investments. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accruals for research and development activities, stock-based compensation and income taxes. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-008339-index-headers.html	Edgar Link	pending
0001628280-17-008339-index.html	Edgar Link	pending
0001628280-17-008339.txt	Edgar Link	pending
0001628280-17-008339-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ptgx-20170630.xml	Edgar Link	completed
ptgx-20170630.xsd	Edgar Link	pending
ptgx-20170630_cal.xml	Edgar Link	unprocessable
ptgx-20170630_def.xml	Edgar Link	unprocessable
ptgx-20170630_lab.xml	Edgar Link	unprocessable
ptgx-20170630_pre.xml	Edgar Link	unprocessable
ptgx10-qq22017.htm	Edgar Link	pending
ptgx10-qq2ex311.htm	Edgar Link	pending
ptgx10-qq2ex312.htm	Edgar Link	pending
ptgx10-qq2ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

2017 Q3 Form 10-Q Financial Statement

#000162828017008339 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX Protagonist Therapeutics, Inc Stock $ptgx

2017 Q3 Form 10-Q Financial Statement

#000162828017008339 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx